Neuroprotective properties of adenosine A2A receptor antagonists in animal models of Parkinson's disease

被引：0
|
作者：
Wardas, Jadwiga [1 ]
机构：
[1] Polish Acad Sci, Inst Pharmacol, Dept Neuropsychopharmacol, PL-31343 Krakow, Poland
来源：
PHARMACOLOGICAL REPORTS | 2011年 / 63卷 / 05期
关键词：
D O I：
10.1016/S1734-1140(11)70670-3
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1283 / 1283
页数：1
相关论文
共 50 条
  • [41] Design and Characterization of Optimized Adenosine A2A/A1 Receptor Antagonists for the Treatment of Parkinson's Disease
    Shook, Brian C.
    Rassnick, Stefanie
    Wallace, Nathaniel
    Crooke, Jeffrey
    Ault, Mark
    Chakravarty, Devraj
    Barbay, J. Kent
    Wang, Aihua
    Powell, Mark T.
    Leonard, Kristi
    Alford, Vernon
    Scannevin, Robert H.
    Carroll, Karen
    Lampron, Lisa
    Westover, Lori
    Lim, Heng-Keang
    Russell, Ronald
    Branum, Shawn
    Wells, Kenneth M.
    Damon, Sandra
    Youells, Scott
    Li, Xun
    Beauchamp, Derek A.
    Rhodes, Kenneth
    Jackson, Paul F.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (03) : 1402 - 1417
  • [42] Novel purine derivatives as selective adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
    Bamford, SJ
    Lerpiniere, J
    Stratton, GC
    Dawson, CE
    Pratt, RM
    Gaur, S
    Weiss, SM
    Knight, TR
    Misra, A
    Jones, J
    Benwell, K
    Upton, R
    Dourish, CT
    Cliffe, IA
    Gillespie, RJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U51 - U52
  • [43] Adenosine receptor A2A antagonists as neuroprotective agents:: Possible involvement of calcium
    Royak, Y
    Mandel, S
    Bick, T
    Green, J
    Jacobson, KA
    Youdim, MBH
    NEUROSCIENCE LETTERS, 1999, : S35 - S35
  • [44] Adenosine A2A antagonists:: potential preventive and palliative treatment for Parkinson's disease
    Morelli, M
    EXPERIMENTAL NEUROLOGY, 2003, 184 (01) : 20 - 23
  • [45] Adenosine A2A antagonists: New therapeutic approach against Parkinson's disease
    Shimada, Junichi
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [46] A2A receptor antagonists:: Potential therapeutic effects in Parkinson's disease
    Morelli, M
    Carta, AR
    Pinna, A
    Pala, P
    BEHAVIOURAL PHARMACOLOGY, 2003, 14 : S2 - S2
  • [47] Adenosine A2A Receptor Antagonists for Parkinson’s DiseaseRationale, Therapeutic Potential and Clinical Experience
    Robert A. Hauser
    Michael A. Schwarzschild
    Drugs & Aging, 2005, 22 : 471 - 482
  • [48] The adenosine A2A receptor as an attractive target for Parkinson's disease treatment
    Chen, JF
    DRUG NEWS & PERSPECTIVES, 2003, 16 (09) : 597 - 604
  • [49] Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease
    Agnati, LF
    Leo, G
    Vergoni, AV
    Martínez, E
    Hockemeyer, J
    Lluis, C
    Franco, R
    Fuxe, K
    Ferré, S
    BRAIN RESEARCH BULLETIN, 2004, 64 (02) : 155 - 164
  • [50] Indenopyrimidines as dual adenosine A2A/A1 antagonists for the treatment of Parkinson\'s disease
    Shook, Brian C.
    Rassnick, Stefanie
    Hall, Daniel
    Rupert, Kenneth
    Heintzelman, Geoffrey
    Hansen, Kristin
    Osborne, Melville
    Davis, Scott
    Westover, Lori
    Boulet, Jamie
    Chakravarty, Devraj
    Bullington, James
    Scannevin, Robert
    Carroll, Karen
    Lampron, Lisa
    Russell, Ronald
    Branum, Shawn
    Wells, Kenneth
    Damon, Sandra
    Youells, Scott
    Li, Xun
    Beauchamp, Derek
    Palmer, David
    Reyes, Mayra
    Demarest, Keith
    Tang, Yuting
    Rhodes, Kenneth
    Jackson, Paul F.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
12345